The opioid epidemic — particularly severe in North America where prescription opioid overprescribing contributed to addiction and overdose mortality crises — has fundamentally altered the regulatory, prescribing, and social environment around morphine and opioid analgesics, with the Morphine Market reflecting the complex tension between reducing opioid misuse harm and maintaining access for patients with legitimate severe pain who have few non-opioid analgesic alternatives.

CDC opioid prescribing guidelines revised in 2022 — moving away from the rigid dose thresholds of the 2016 guidelines that produced unintended harm through abrupt opioid discontinuation in stable chronic pain patients — emphasized individualized patient-centered assessment while maintaining caution about initiating high-dose long-term opioid therapy for non-cancer chronic pain. The pendulum swing from 2016's prescribing restriction emphasis to 2022's patient-centered flexibility reflects the evidence base demonstrating that overcorrection created significant harm for legitimate pain patients.

Prescription drug monitoring programs — statewide databases recording opioid prescriptions that prescribers and pharmacists can query before prescribing or dispensing — have been implemented across all US states and in numerous international jurisdictions, reducing the doctor-shopping practices that facilitated prescription opioid diversion. PDMP query requirements before opioid prescribing have become standard clinical practice integrated into electronic health record workflows.

Extended-release abuse-deterrent morphine formulations — incorporating physical or chemical barriers making the tablet difficult to crush, dissolve, or extract for injection or insufflation — represent pharmaceutical technology reducing misuse potential of morphine ER without limiting analgesic efficacy for legitimate oral administration. Embeda combining morphine with sequestered naltrexone that releases only upon crushing provides an opioid receptor antagonist barrier to injection misuse.

Do you think abuse-deterrent opioid formulations have meaningfully reduced opioid misuse at the population level, or have they primarily shifted misuse toward more accessible formulations and illicit opioids?

FAQ

What is an abuse-deterrent opioid formulation? Abuse-deterrent opioid formulations incorporate physical or chemical barriers making the medication difficult to misuse through crushing for insufflation or injection, maintaining oral analgesic efficacy for legitimate use while reducing misuse potential.

What is a prescription drug monitoring program? PDMPs are state or national databases recording opioid and controlled substance prescriptions, queried by prescribers and pharmacists before prescribing to identify patients receiving multiple prescriptions from different providers.

#MorphineMarket #OpioidCrisis #MorphinePrescribing #AbuseDeterrent #PrescriptionMonitoring #PainManagement